Abuse risks and routes of administration of different prescription opioid compounds and formulations

Harm Reduction Journal

Volumn 8, Issue , 2011, Pages

  Butler, Stephen F ^a   Black, Ryan A ^a   Cassidy, Theresa A ^a   Dailey, Taryn M ^a   Budman, Simon H ^a  

^a INFLEXXION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS OXYCODONE PLUS OXYCODONE TEREPHTHALATE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE DERIVATIVE; OXYCODONE; OXYMORPHONE; PERCOCET; PRESCRIPTION DRUG;

ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; DATA ANALYSIS; DRUG ABUSE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRESCRIPTION; RISK ASSESSMENT; SUBSTANCE ABUSE; UNITED STATES;

EID: 80054118887     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-8-29     Document Type: Article

References (55)

1. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130. 10.1016/j.jpain.2008.10.008, 19187889.
2. Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain 2008, 138:507-513. 10.1016/j.pain.2008.01.027, 18342447.
3. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National Findings. NSHUD Series H-36 2009, Rockville, MD: Office of Applied Studies, Substance Abuse and Mental Health Services Administration.
4. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report 2010, Centers for Disease Control and Prevention.
5. Centers for Disease Control and Prevention Unintentional Drug Poisoning in the United States 2010, Centers for Disease Control and Prevention.
6. Johnston LD, O'Malley PM, Bachman JG, Schulenburg JE. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2008. 2009, Bethesda: National Institutes on Drug Abuse, National Institutes of Health.
7. Substance Abuse and Mental Health Services Administration Treatment Episode Data Set (TEDS) 1996-2006. National admissions to substance abuse treatment services 2008, Rockville, MD: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration.
8. National Institute on Drug Abuse Epidemiologic trends in drug abuse. Proceedings of the Community Epidemiology Work Group 2007, National Institute on Drug Abuse.
9. Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduction 2009, 6.
10. Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs 2010, 70:1657-1675. 10.2165/11537940-000000000-00000, 20731474.
11. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream?. Curr Rheumatol Rep 2008, 10:11-18. 10.1007/s11926-008-0003-z, 18457606.
12. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009, 10:S134-133.
13. Wick JY. Drug-abuse deterrent formulations. Consult Pharm 2009, 24:356-362. 10.4140/TCP.n.2009.356, 19555144.
14. Chitwood DD, Comerford M, Sanchez J. Prevalence and risk factors for HIV among sniffers, short-term injectors, and long-term injectors of heroin. J Psychoactive Drugs 2003, 35:445-453. 10.1080/02791072.2003.10400491, 14986873.
15. Latkin CA, Knowlton AR, Sherman S. Routes of drug administration, differential affiliation, and lifestyle stability among cocaine and opiate users: implications to HIV prevention. J Subst Abuse 2001, 13:89-102. 10.1016/S0899-3289(01)00070-0, 11547627.
16. Razak MH, Jittiwutikarn J, Suriyanon V, Vongchak T, Srirak N, Beyrer C, Kawichai S, Tovanabutra S, Rungruengthanakit K, Sawanpanyalert P, Celentano DD. HIV prevalence and risks among injection and noninjection drug users in northern Thailand: need for comprehensive HIV prevention programs. J Acquir Immune Defic Syndr 2003, 33:259-266. 10.1097/00126334-200306010-00023, 12794564.
17. Wright C, Kramer ED, Zalman MA, Smith MY, Haddox JD. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend 2006, 83(Suppl 1):S68-76.
18. Food and Drug Administration Briefing Information for the July 22-23, 2010 Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee 2010, Bethesda, MD, Food and Drug Administration.
19. Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, Magura S, Haddox JD. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007, 90:64-71. 10.1016/j.drugalcdep.2007.02.012, 17386981.
20. NSDUH 2007 National Survey on Drug Use & Health:National Results 2007, Rockville, MD: Substance Abuse Mental Health Services Administration, NSDUH.
21. Substance Abuse and Mental Health Services Administration The DAWN Report: Trends in Emergency Department Visits Involving Nonmedical Use of Narcotic Pain Relievers 2010, Rockville, MD: Office of Applied Studies, Substance Abuse and Mental Health Services Administration.
22. Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, Brownstein JS, Benneyan JC, Green TC, Katz N. National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™): A real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiology and Drug Safety 2008, 17:1142-1154. 10.1002/pds.1659, 18932173.
23. Cicero TJ, Adams EH, Geller A, Inciardi JA, Munoz A, Schnoll SH, Senay EC, Woody GE. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999, 57:7-22. 10.1016/S0376-8716(99)00041-1, 10617309.
24. Arfken CL, Cicero TJ. Postmarketing surveillance for drug abuse. Drug Alcohol Depend 2003, 70:S97-105. 10.1016/S0376-8716(03)00102-9, 12759200.
25. Hennekens CH, Buring JE. Epidemiology in medicine 1987, Boston: Little, Brown, and Co.
26. Dasgupta N, Kramer ED, Zalman MA, Carino S, Smith MY, Haddox JD, Wright C. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006, 82:135-142. 10.1016/j.drugalcdep.2005.08.019, 16236466.
27. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. Journal of Nervous and Mental Disease 1980, 168:26-33. 10.1097/00005053-198001000-00006, 7351540.
28. McLellan AT, Kushner H, Metzger D, Peters R. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9:199-213. 10.1016/0740-5472(92)90062-S, 1334156.
29. Hendricks VM, Kaplan CD, VanLimbeek J, Geerlings P. The Addiction Severity Index: Reliability and validity in a Dutch addict population. Journal of Substance Abuse Treatment 1989, 6:133-141. 10.1016/0740-5472(89)90041-X, 2746712.
30. Butler SF, Newman FL, Cacciola JS, Frank A, Budman SH, McLellan AT, Ford S, Blaine J, Gastfriend D, Moras K, et al. Predicting Addiction Severity Index (ASI) interviewer severity ratings for a computer-administered ASI. Psychological Assessment 1998, 10:399-407.
31. Butler SF, Budman SH, Goldman RJ, Newman FL, Beckley KE, Trottier D, Cacciola JS. Initial validation of a computer-administered Addiction Severity Index: the ASI-MV. Psychol Addict Behav 2001, 15:4-12.
32. Butler SF, Redondo JP, Fernandez KC, Villapiano A. Validation of the Spanish Addiction Severity Index Multimedia Version (S-ASI-MV). Drug and Alcohol Dependence 2009, 99:18-27. 10.1016/j.drugalcdep.2008.06.012, 2651671, 18718727.
33. United States Department of Health & Human Services (HHS) Basic HHS Policy for Protection of Human Research Subjects 2005, Office for Human Research Protections (OHRP), United States Department of Health & Human Services (HHS).
34. FHOP Family health outcomes project unique identifiers, discussion, recommendations and testing 1995, FHOP.
35. Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Cicero TJ, Gourlay D, Inciardi JA, et al. Foundations of opioid risk management. Clin J Pain 2007, 23:103-118. 10.1097/01.ajp.0000210953.86255.8f, 17237659.
36. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: A review. Pain 1993, 52:137-147. 10.1016/0304-3959(93)90125-9, 8455961.
37. Substance Abuse and Mental Health Services Administration Office of Applied Studies National Survey of Substance Abuse Treatment Services (N-SSATS): 2009. Data on Substance Abuse Treatment Facilities 2010, Rockville, MD, Substance Abuse and Mental Health Services Administration Office of Applied Studies.
38. Connors GJ, Maisto SA. Drinking reports from collateral individuals. Addiction 2003, 92:21-29.
39. Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the science and challenges for research. Addiction 2003, 98:1-12.
40. Neale J, Robertson M. Comparisons of self-report data and oral fluid testing in detecting drug use amongst new treatment clients. Drug Alcohol Depend 2003, 71:57-64. 10.1016/S0376-8716(03)00053-X, 12821206.
41. Secades-Villa R, Fernandez-Hermida JR. The validity of self-reports in a follow-up study with drug addicts. Addict Behav 2003, 28:1175-1182. 10.1016/S0306-4603(02)00219-8, 12834660.
42. Yacoubian GS, Urbach BJ. To pee or not to pee: reconsidering the need for urinalysis. Drug Educ 2002, 32:261-270.
43. Solbergsdottir E, Bjornsson G, Gudmundsson LS, Tyrfingsson T, Kristinsson J. Validity of self-reports and drug use among young people seeking treatment for substance abuse or dependence. J Addict Dis 2004, 23:29-38. 10.1300/J069v23n01_03, 15077838.
44. Chermack ST, Roll JJ, Reilly MM, Davis L, Kilaru U, Grabowski J. Comparison of patient self-reports and urinalysis results obtained under naturalistic methadone treatment conditions. Drug Alcohol Depend 2000, 59:43-49. 10.1016/S0376-8716(99)00106-4, 10706974.
45. Tassiopoulos K, Bernstein J, Heeren T, Levenson S, Hingson R, Bernstein E. Hair testing and self-report of cocaine use by heroin users. Addiction 2004, 99:590-597. 10.1111/j.1360-0443.2004.00685.x, 15078233.
46. Butler SF, Villapiano A, Malinow A. The effect of computer-mediated administration on self-disclosure of problems on the Addiction Severity Index. J Addiction Med 2009, 3:194-203.
47. Gfroerer J, Eyerman J, Chromy J. Redesigning an ongoing national household survey: Methodological issues 2002, Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
48. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006, 15:618-627. 10.1002/pds.1276, 16862602.
49. Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data. Drug Safety 2007, 30:533-540. 10.2165/00002018-200730060-00007, 17536879.
50. Jauncey M, Taylor L, Degenhardt L. Classification of opioid-induced deaths in Australia: Implications for surveillance. Drug and Alcochol Review 2005, 24:401-409.
51. Food and Drug Administration FDA Public Health Advisory, Important Information for the Safe Use of Fentora (fentanyl buccal tablets) 2007, Bethesda, MD: Center for Drug Evaluation and Research, Food and Drug Administration.
52. Food and Drug Administration FDA Public Health Advisory, Methadone Use for Pain Control May Result in Death and Life-Threatening Changes in Breathing and Heart Beat 2007, Bethesda, MD: Center for Drug Evaluation and Research, Food and Drug Administration.
53. Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 2008, 96:1-15. 10.1016/j.drugalcdep.2008.03.001, 2744317, 18436394.
54. Rappaport BA. Joint Meeting of the Anesthetic and Life Support Drug Advisory Committee and Drug Satefy & Risk Management Advisory Committee 2008, FDA: Center for Drug Evaluation and Research.
55. Deddens J, Petersen M, X L. Estimation of prevalence ratios when PROC GENMOD does not converge, SUGI28. 2003,